Search

Your search keyword '"Benagiano, G."' showing total 608 results
Start Over Author "Benagiano, G."
608 results on '"Benagiano, G."'

1. Uterine fibroids: an update on current and emerging medical treatment options

Author

Farris M, Bastianelli C, Rosato E, Brosens I, and Benagiano G

Subjects
Uterine myomas, progestin, gonadotropin-releasing hormone receptor blockers, selective progesterone receptor modulators, antiestrogens., Therapeutics. Pharmacology, RM1-950
Abstract

Manuela Farris,1,2 Carlo Bastianelli,1 Elena Rosato,1 Ivo Brosens,3 Giuseppe Benagiano1 1Department of Gynecology, Obstetrics and Urology, Sapienza, University of Rome, Rome, Italy; 2The Italian Association for Demographic Education, Rome, Italy; 3Faculty of Medicine, KU Leuven, Leuven, Belgium Abstract: Uterine fibroids are the most common gynecological disorder, classically requiring surgery when symptomatic. Although attempts at finding a nonsurgical cure date back to centuries, it is only around the middle of the last century that serious attempts at a medical treatment were carried out. Initially, both progestins and estrogen–progestin combinations have been utilized, although proof of their usefulness is lacking. A major step forward was achieved when peptide analogs of the GnRH were introduced, first those with superagonist properties and subsequently those acting as antagonists. Initially, the latter produced side effects preventing their routine utilization; eventually, this problem was overcome following the synthesis of cetrorelix. Because both types of analogs produce hypoestrogenism, their use is limited to a maximum of 6 months and, for this reason, today they are utilized as an adjuvant treatment before surgery with overall good results. Over the last decade, new, nonpeptidic, orally active GnRH-receptor blockers have also been synthesized. One of them, Elagolix, is in the early stages of testing in women with fibroids. Another fundamental development has been the utilization of the so-called selective progesterone receptor modulators, sometimes referred to as “antiprogestins”. The first such compound to be applied to the long-term treatment of fibroids was Mifepristone; today, this compound is mostly used outside of Western Countries, where the substance of choice is Ulipristal acetate. Large clinical trials have proven the effectiveness of Ulipristal in the long-term medical therapy of fibroids, although some caution must be exercised because of the rare occurrence of liver complications. All selective progesterone receptor modulators produce unique endometrial changes that are today considered benign, reversible, and without negative consequences. In conclusion, long-term medical treatment of fibroids seems possible today, especially in premenopausal women. Keywords: uterine myomas, progestin, gonadotropin-releasing hormone receptor blockers, selective progesterone receptor modulators, antiestrogens

Published
2019

5. The Di Bella Multitherapy Trial

Author

Liberati, Alessandro, Magrini, Nicola, Patoia, Lucio, Pagliaro, Luigi, Raschetti, R., Greco, D., Menniti-Ippolito, F., Spila-Alegiani, S., Traversa, G., Benagiano, G., Bruzzi, P., Müllner, Marcus, and Evans, Stephen J. W.

Published
1999

30. Early stage management of ovarian endometrioma to prevent infertility

Author

Brosens, I., Puttemans, P., Gordts, Sy., Campo, R., Gordts, S., and Benagiano, G.

Subjects
surgery, fertility, follicle reserve, Vision, diagnosis, vascularisation, Endometrioma
Abstract

There are now convincing data showing that cystectomy of the endometrioma is not only no cure of infertility, but may harm follicle reserve. The question arises why is cystectomy for an endometrioma, in contrast with other -benign cysts, a risk for follicle reserve and how can ovarian damage be prevented. Surgical specimens of ovaries with endometrioma in situ show in the majority of cases manifestly a combined -extra-ovarian and intra-ovarian pathology with the cortex invaginated to form a pseudocyst. The extra-ovarian pathology includes endometrial lining of the cortex, bleeding and adhesions with surrounding tissues. The intra-ovarian pathology is characterized by microscopic stromal implants, fibrosis, smooth muscle metaplasia and -arteriosclerosis, all affecting follicle reserve in the endometrioma bed. Clinically, ovarioscopy allows differential diagnosis (e.g. luteal cyst) and evaluation of the degree of fibrosis and darkening of the cortical wall. Transvaginal colour Doppler sonography can demonstrate the presence and extent of devascularisation in the endometrioma bed. Given this reality, surgery should be based on evaluation of the pathology of the endometrioma bed, but not on the mere size of the chocolate cyst. The main clinical problem is indeed the delayed diagnosis and consequently advanced irreversible cortical damage. Therefore, the sooner endometriomas are diagnosed, the better, because it increases the chances that vascularisation of the endometrioma bed is preserved. Finally, ablation, but not excision is the treatment of choice. The diagnosis of endometriosis is traditionally based on laparoscopy, but in a sexually active adolescent transvaginal endoscopy can be proposed.

Published
2013

32. Discussion (day 1 session 1): Assisted conception and moral philosophy

Author

Gladys B. White, Roger V. Short, Anne McLaren, John A. Robertson, Landau R, Te Velde E, David J. Galton, Michael Lockwood, John Harris, Søren Holm, Robert G Edwards, Albert B, Golombok S, Gedis Grudzinskas, Lisa Bortolotti, Benagiano G, Peter Brinsden, and Julian Savulescu

Subjects
Psychoanalysis, Eugenics, Reproductive Techniques, Assisted, media_common.quotation_subject, Single parent, MEDLINE, Homosexuality, Female, Obstetrics and Gynecology, Morals, Single Parent, Moral philosophy, Reproductive Medicine, Pregnancy, Humans, Ethics, Medical, Female, Bioethical Issues, Homosexuality, Session (computer science), Psychology, Developmental Biology, media_common
Published
2005
Full Text
View/download PDF

35. Bone fractures after menopause

Author

Barlow, D.H., Bouchard, P., Brandi, M.L., Evers, J.L.H., Glasier, A., Negri, E., Papapoulos, S.E., Ralston, S.H., Rizzoli, R., Baird, D.T., Collins, J., Benagiano, G., Crosignani, P.G., Vecchia, C. la, Volpe, A., and ESHRE Capri Workshop Grp

Subjects
falls bone fractures osteoporosis ageing bone mineral density randomized controlled-trials osteoporosis risk-assessment vitamin-d supplementation yearly zoledronic acid postmenopausal women mineral density hip fracture nonvertebral fractures cannabinoid receptor hormone-therapy
Abstract

Every year 30% of individuals above age 65 fall, and falls are the principal cause of bone fractures. To reduce fracture incidence requires both prevention of falls and maintenance of bone strength. PubMed searches were performed, for studies of the epidemiology of fractures, bone physiology, endocrine effects, osteoporosis measurement, genetics, prevention and effectiveness. Topic summaries were presented to the Workshop Group and omissions or disagreements were resolved by discussion. Ageing reduces bone strength in post-menopausal women because estrogen deficiency causes accelerated bone resorption. Bone mineral density (BMD) decreased more than 2.5 standard deviation below the mean of healthy young adults defines osteoporosis, a condition associated with an increased risk of fractures. Risk factors such as age and previous fracture are combined with BMD for a more accurate prediction of fracture risk. The most widely used assessment tool is FRAX (TM) which combines clinical risk factors and femoral neck BMD. General preventive measures include physical exercise to reduce the risk of falling and vitamin D to facilitate calcium absorption. Pharmacological interventions consist mainly in the administration of inhibitors of bone resorption. Randomized controlled trials show treatment improves BMD, and may reduce the relative fracture risk by about 50% for vertebral, 20-25% for non-vertebral and up to 40% for hip fractures although the absolute risk reductions are much lower. Although diagnosis of osteoporosis is an important step, the threshold for treatment to prevent fractures depends on additional clinical risk factors. None of the presently available treatment options provide complete fracture prevention.

Published
2010

40. Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy

Author

Crosignani, Pg, Nappi, C, Ronsini, S, Bruni, V, Marelli, S, Sonnino, D, Affronti, G, Benagiano, G, Benedetto, C, Bolis, G, Cianci, A, Fedele, L, Garsia, S, Genazzani, Andrea, Gherzi, R, Masellis, G, Melis, G, Moscarini, M, Piccione, E, Quartararo, P, Ragni, N, Scagliola, P, Schönauer, S, Sismondi, P, Venturini, Pl, Volpe, A, Italian EVRA Contrast Study Group, Zullo F., Crosignani, Pg, Nappi, Carmine, Ronsini, S, Bruni, V, Marelli, S, Sonnino, D., Crosignani, Pier Giorgio, Ronsini, Salvatore, Bruni, Vincenzina, Marelli, Silvia, Sonnino, Davide, Affronti, G., Benagiano, G., Benedetto, C., Bolis, G., Cianci, A., Fedele, L., Garsia, A., Genazzani, A. R., Gherzi, R., Masellis, G., Melis, G., Moscarini, M., Piccione, E., Quartararo, P., Ragni, N., Scagliola, P., Schönauer, S., Sismondi, P., Venturini, P. L., Volpe, A., and Zullo, F.

Subjects
Ethinyl Estradiol-Norgestrel Combination, systolic blood pressure, drug safety, personal experience, Birth control, Oxime, Pregnancy, Obstetrics and Gynaecology, Oximes, Medicine, Norelgestromin, norelgestromin, birth control, media_common, ethinylestradiol plus norelgestromin, drug derivative, ethinylestradiol plus norgestrel, norgestrel, oral contraceptive agent, oxime, adult, article, barrier contraception, breast tension, clinical trial, diastolic blood pressure, drug efficacy, drug induced headache, drug tolerability, female, hormonal contraception, human, Italy, local skin reaction, major clinical study, mastalgia, multicenter study, nausea, oral contraception, patient compliance, patient satisfaction, pruritus, pulse rate, quality of life, spotting, vagina contraception, adolescent, intradermal drug administration, middle aged, pregnancy, statistics, treatment outcome, Administration, Cutaneous, Adolescent, Adult, Contraceptives, Oral, Combined, Female, Humans, Middle Aged, Norgestrel, Patient Compliance, Patient Satisfaction, Quality of Life, Treatment Outcome, Young Adult, Medicine(all), Combined, Obstetrics, lcsh:Public aspects of medicine, Obstetrics and Gynecology, Contraceptives, General Medicine, Drug Combinations, Family planning, Pill, Administration, Developed country, Contraceptive patch, Human, medicine.drug, Research Article, Oral, Administration, Cutaneou, medicine.medical_specialty, media_common.quotation_subject, lcsh:Gynecology and obstetrics, Adverse effect, lcsh:RG1-991, Gynecology, business.industry, lcsh:RA1-1270, Cutaneous, Reproductive Medicine, Hormonal contraception, Settore MED/40 - Ginecologia e Ostetricia, business
Abstract

Background For many women finding the right contraceptive method can be challenging and consistent and correct use over a lifetime is difficult. Even remembering to take a birth control pill every day can be a challenge. The primary objective of this study was to evaluate women's experience with a weekly ethinylestradiol/norelgestromin contraceptive patch (EE/NGMN patch), given new technologies recently developed in hormonal contraception to increase women's options in avoiding daily dosing. Methods In 24 Italian sites, 207 women received the EE/NGMN patch for up to 6 cycles. At study end, overall satisfaction and preference, as well as compliance, efficacy and safety, were evaluated. Results 175 women (84.5%) completed the study. The overall satisfaction rate was 88%; convenience and once-a-week frequency of the patch were especially appreciated. At baseline, 82 women (39.4%) were using a contraceptive method, mainly oral contraceptives and barrier methods, but only 45.1% were very satisfied/satisfied; after 6 months with the patch, 86.3% of this subset was very satisfied/satisfied. Considering the method used in the 3 months before the study entry, 78.1% strongly preferred/preferred the patch, for convenience (53.9%), ease of use/simplicity (28.9%), fewer (9.2%) and less severe (2.6%) side effects. Compliance was very high: 1034/1110 cycles (93.2%) were completed with perfect compliance and the mean subject's compliance score was 90%. One on-therapy pregnancy occurred. The patch was safe and well tolerated: adverse events frequency was low, with predominantly single reports of each event. Most of them started and subsided during cycle 1. Conclusion This study demonstrated that the EE/NGMN patch is associated with high satisfaction levels and excellent compliance. At study end, the majority of women indicated that they would continue using the patch.

Published
2009

41. Clinical Synthesis Conference. Hormone replacement therapy (Reprinted from The Lancet, vol 354, pg 152-155, 1999)

Author

Grant, C, Gray, A, Paoletti, R, Thornton, H, von Kleist, S, Beral, V, Burger, H, Creasman, W, Delman, P, Kenemans, P, Leake, RE, Meade, TW, Skoog, I, Andrews, WC, Autier, P, Birkhauser, M, Fugh-Berman, A, Bush, T, Calle, E, Franceschi, S, Holmberg, L, Stampfer, M, Trimble, E, Duffy, S, Robertson, C, Walker, AM, Boyle, P, Benagiano, G, Horton, R, Radda, G, Sharp, D, Cucinotta, S, Castelli, M, Manenti, S, Monticelli, C, Kahle, M, Russell-Edu, W, Sabatini, C, Veronesi, U, and HRT, CSP

Published
2000

42. Hormone replacement therapy. Clinical Synthesis Panel on HRT

Author

Grant, C, Gray, A, Paoletti, R, Thornton, H, Von Kleist, S, Beral, V, Burger, H, Creasman, W, Delmas, P, Kenemans, P, Leake, RE, Meade, TW, Skoog, I, Andrews, WC, Autier, P, Birkhauser, M, Fugh-Berman, A, Bush, T, Calle, E, Franceschi, S, Holmberg, L, Stampfer, M, Trimble, E, Duffy, S, Robertson, C, Walker, AM, Boyle, P, Benagiano, G, Horton, R, Radda, G, Sharp, D, Cucinotta, S, Castelli, M, Manenti, S, Monticelli, C, Kahle, M, Russell-Edu, W, Sabatini, C, and Veronesi, U

Published
1999

43. The Unconventional Di Bella Cancer Treatment. A Reflection on the Italian Experience

Author

Traversa, G, Maggini, M, Menniti Ippolito, F, Bruzzi, P, Chiarotti, F, Greco, D, Spila Alegiani, S, Raschetti, R, Benagiano, G, Caffari, B, Da Cas, R, De Mei, B, Di Giovambattista, G, Modigliani, S, Popoli, P, Ruggeri, P, Tomino, C, Gamucci, T, Amadori, D, Buiatti, E, Ciranni, E, Cognetti, F, Colucci, G, Conte, Pf, Di Bella, G, Iacobelli, S, Mandelli, F, Marubini, E, Massotti, M, Monfardini, S, Oleari, F, Sannazzari, Gl, Tomatis, L, Veronesi, U, Cellerino, R, Antognoli, S, Berardi, R, Bracci, R, Lippe, P, Pulita, F, Di Vito, F, Martinod, D, Musi, M, Veronesi, A, Lazzarini, R, Attolico, V, Giotta, F, Longo, M, Maiello, E, Tura, S, Gherlinzoni, F, Tani, M, Amor, H, Borona, P, Giradi, F, Graiff, C, Broccia, G, Corona, Mg, Desogus, A, Mascia, V, Pasqualucci, S, Failla, G, Aiello, Rm, Cordio, S, Finocchiaro, P, Melena, E, Tursi, De, Scognamiglio, Mt, Tinati, N, Maltoni, M, Nanni, O, Scardovi, F, Serra, P, Rosso, R, Boccardo, F, Bapr, A, Coli, T, Grimaldi, M, Cascinalli, N, Ascani, L, Bajetta, E, Bidoli, P, Cassata, A, De Candis, D, Giannessi, W, Procopio, G, Di Donato, S, Boiardi, A, Cerri, D, Eoli, M, Silvani, A, Colleoni, M, Rotmensz, N, Morfadini, S, Comella, G, De Matteis, A, Gravina, A, Gridelli, C, Perrone, F, Salzano, Mr, Sandomenico, C, Battista, C, Iodice, G, Fico, R, Nicchia, A, Lise, M, De Salvo GL, Di lenardo, E, Iadicicco, F, Agostara, Bb, Cafarelli, I, Tonato, M, Radicchi, F, Sorbolini, S, Taschini, O, Carmignani, A, Del Mastro, L, Gennari, A, Orlandini, C, Manzione, L, Dinota, A, Lombardi, G, Gasparini, G, Arena, Mg, Fanelli, M, Modafferi, F, Fazi, P, Mauro, F, Martelli, M, Ricci, C, Vignetti, M, D’Alessio, A, Giannarelli, D, Magnani, E, Rellecati, P, Ruggeri, Em, Zeuli, Borgognone, M, Chio', Adriano, Gasco, A, Ragona, R, Sacco, M, Soffietti, Riccardo, Tessa, M, Pileri, A, Galligioni, E, Lucenti, A, Moltreer, F, Paolazzi, F, Bianco, Ar, Labianca, R, Rossi Ferrini PL, Simonetti, G, and Sobrero, A.

Published
1999

45. Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy

Author

Raschetti, R, Bruzzi, P, Greco, D, Maggini, M, Menniti Ippolito, F, Spila Alegiani, S, Traversa, G, Benagiano, G, Caffari, B, Chiarotti, F, Da Cas, R, De Mei, B, Di Giovambattista, G, Modigliani, S, Popoli, P, Ruggeri, P, Tomino, C, Gamucci, T, Amadori, D, Buiatti, E, Ciranni, E, Cognetti, F, Colucci, G, Conte, Pf, Di Bella, G, Iacobelli, S, Mandelli, F, Marubini, E, Massotti, M, Monfardini, S, Oleari, F, Sannazzari, Gl, Tomatis, L, Veronesi, U, Cellerino, R, Antognoli, S, Berardi, R, Bracci, R, Lippe, P, Pulita, F, Di Vito, F, Martinod, D, Musi, M, Veronesi, A, Lazzarini, R, Attolico, V, Giotta, F, Longo, M, Maiello, E, Tura, S, Gherlinzoni, F, Tani, M, Amor, H, Borona, P, Giradi, F, Graiff, C, Broccia, G, Corona, Mg, Desogus, A, Mascia, V, Pasqualucci, S, Failla, G, Aiello, Rm, Cordio, S, Finocchiaro, P, Melena, E, Tursi, De, Scognamiglio, Mt, Tinati, N, Maltoni, M, Nanni, O, Scardovi, F, Serra, P, Rosso, R, Boccardo, F, Bapr, A, Coli, T, Grimaldi, M, Cascinalli, N, Ascani, L, Bajetta, E, Bidoli, P, Cassata, A, De Candis, D, Giannessi, W, Procopio, G, Di Donato, S, Boiardi, A, Cerri, D, Eoli, M, Silvani, A, Colleoni, M, Rotmensz, N, Morfadini, S, Comella, G, De Matteis, A, Gravina, A, Gridelli, C, Perrone, F, Salzano, Mr, Sandomenico, C, Battista, C, Iodice, G, Fico, R, Nicchia, A, Lise, M, De Salvo GL, Di lenardo, E, Iadicicco, F, Agostara, Bb, Cafarelli, I, Tonato, M, Radicchi, F, Sorbolini, S, Taschini, O, Carmignani, A, Del Mastro, L, Gennari, A, Orlandini, C, Manzione, L, Dinota, A, Lombardi, G, Gasparini, G, Arena, Mg, Fanelli, M, Modafferi, F, Fazi, P, Mauro, F, Martelli, M, Ricci, C, Vignetti, M, D’Alessio, A, Giannarelli, D, Magnani, E, Rellecati, P, Ruggeri, Em, Zeuli, Borgognone, M, Chio', Adriano, Gasco, A, Ragona, R, Sacco, M, Soffietti, Riccardo, Tessa, M, Pileri, A, Galligoini, E, Lucenti, A, Moltreer, F, Paolazzi, F, Bianco, Ar, Labianca, R, Rossi Ferrini PL, Simonetti, G, and Sobrero, A.

Subjects
Papers
Published
1999

48. CONTRACCEZIONE

Author

Benagiano, G and Primiero, Francesco Maria

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results